Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 7Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

enzalutamide 33Abiraterone Acetate 29apalutamide 26Prednisone 26Radiotherapy 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 22Radiosurgery 19darolutamide 18Docetaxel 17Gonadotropin-Releasing Hormone 16acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 13gallium 68 PSMA-11 12bicalutamide 12Specimen Handling 12Radiotherapy, Intensity-Modulated 12abiraterone 11Radiation 11pembrolizumab 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Triptorelin Pamoate 8Standard of Care 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Finasteride × Clear all
NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

University of Chicago

Phase NA Active not recruiting
74 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡